These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Belhassen M; Dalon F; Nolin M; Van Ganse E Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414 [TBL] [Abstract][Full Text] [Related]
9. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352 [TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. Raghu G Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954769 [TBL] [Abstract][Full Text] [Related]
12. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523 [TBL] [Abstract][Full Text] [Related]
13. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050 [TBL] [Abstract][Full Text] [Related]
15. Evaluation and management of Idiopathic Pulmonary Fibrosis. Kishaba T Respir Investig; 2019 Jul; 57(4):300-311. PubMed ID: 30853366 [TBL] [Abstract][Full Text] [Related]
16. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Moodley Y; Corte T; Richeldi L; King TE Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967 [TBL] [Abstract][Full Text] [Related]
17. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400 [TBL] [Abstract][Full Text] [Related]